Wall Street Analysts See a 158.17% Upside in Immunome (IMNM): Can the Stock Really Move This High?

Core Viewpoint - Immunome, Inc. (IMNM) has seen a 19.1% increase in share price over the past four weeks, closing at $9.49, with analysts projecting a potential upside of 158.2% based on a mean price target of $24.50 [1][11]. Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $5.76, indicating variability among analysts [2]. - The lowest price target of $20 suggests an 110.8% increase, while the highest target of $38 indicates a potential surge of 300.4% [2]. - A low standard deviation signifies a strong agreement among analysts regarding the stock's price movement [9]. Earnings Estimates and Analyst Sentiment - Analysts have shown strong agreement in revising earnings per share (EPS) estimates higher, which correlates with potential stock price increases [11]. - Over the last 30 days, four estimates have been revised upward, leading to a 14.8% increase in the Zacks Consensus Estimate for the current year [12]. - IMNM holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13].